candida antigen
Phase 2Biologic
candida antigen is one of 53 biologic programs targeting Common Wart. It is currently in Phase 2.
2
Indications
5
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Papilloma
#DrugCompanyPhaseTrials
1Cervarix
GSKPhase 3
GSK 257049
GSKPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Gardasil
Merck & Co.Phase 3
Havrix
GSKPhase 3
Engerix-B
GSKPhase 3
Keytruda
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Taxol
TevaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Genital Warts1 trial
Efficacy of Intralesional MMR Vaccine,Intralesional Candidal Antigen&Topical Podophyllin in Treatment of Genital Warts
Unknown status·—·Phase 3·NCT03853785·45 enrolled
Cutaneous Warts1 trial
Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts
Unknown status·—·Phase 3·NCT03158168·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for candida antigen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Arkansas